{"filings":[{"id":1249998,"accession_number":"0001628280-26-045194","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2026-06-24T20:22:04+00:00","items":["5.07","9.01"],"status":"ready","headline":"C4 Therapeutics stockholders elect directors, approve equity plan amendment including pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three Class III directors (Hirsch, Fawell, Koppikar) re-elected with 47.8M–46.5M votes for each.","Non-binding advisory vote on executive compensation approved: 54.9M for, 1.07M against.","Stockholders ratified KPMG as independent auditor for fiscal 2026 with 76.9M votes in favor.","Amendment to 2020 Stock Plan approved: includes pre-funded warrants in Outstanding Shares definition for evergreen increase calculation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":981997,"accession_number":"0001628280-26-042365","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2026-06-11T11:04:42+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"C4T Phase 1 cemsidomide in RRMM shows 53% ORR at RP2D, MRD negativity, well-tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["53% ORR at 100 µg RP2D; 36% ORR across all doses (73 patients, median 7 prior lines).","MRD negativity achieved in two patients at RP2D (sCR and CR); responses deepened over time.","Median PFS 3.9 months (95% CI 3.2–5.6); median DOR 7.9 months (95% CI 3.0–NE).","No treatment discontinuations related to cemsidomide; manageable neutropenia (58% Grade 3/4).","ORR consistent across subgroups: prior CAR-T/TCE 53% at RP2D; prior BCMA 47% at RP2D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470482,"accession_number":"0001628280-26-035542","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2026-05-15T20:03:00+00:00","items":["5.02"],"status":"ready","headline":"C4 Therapeutics CFO Adams assumes principal accounting officer; Mossler departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Mossler to cease as Chief Accounting Officer effective May 15, 2026; departure not due to any disagreement.","CFO Kendra R. Adams designated as principal accounting officer, effective May 15, 2026.","Adams receives no additional compensation for assuming the additional role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22287,"accession_number":"0001628280-26-033861","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2026-05-12T11:05:23+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics Q1 2026 net loss $25.1M; cash $268.3M; new Roche DAC collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.2M (down from $7.2M YoY); net loss $25.1M ($0.20 EPS) vs $26.3M ($0.37 EPS).","Cash $268.3M at March 31, 2026; runway to end of 2028.","Decision to not advance CFT8919 (EGFR L858R degrader) outside Greater China.","New collaboration with Roche for degrader-antibody conjugates; $20M upfront payment received.","Cemsidomide Phase 2 MOMENTUM trial enrollment on track; Phase 1b with elranatamab first patient dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":6152000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94506,"accession_number":"0001628280-26-024583","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"C4 Therapeutics amends bylaws to designate exclusive forum for federal securities claims","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved by-laws amendment effective April 9, 2026 designating U.S. District Courts for Massachusetts and Delaware as exclusive forums for Securities Act and Exchange Act claims.","Amendment responds to recent changes in Delaware General Corporation Law regarding forum selection provisions.","Company may consent in writing to an alternative forum; full text filed as Exhibit 3.1.","No financial impact; governance change only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94505,"accession_number":"0001628280-26-024336","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics enters Roche DAC collaboration; $20M upfront, >$1B milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$20M upfront from Roche for two DAC programs targeting undisclosed oncology targets.","Eligible for over $1B in discovery, regulatory, and commercial milestones plus tiered royalties (mid-single to low-double digit).","Roche responsible for all development, regulatory, manufacturing, and commercialization costs.","Option for a third target with additional payment, milestones, and royalties.","Leverages C4T's TORPEDO platform for degrader payloads and Roche's ADC expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106941,"accession_number":"0001628280-26-011971","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics reports Q4 net loss $20.5M, cash $297M; cemsidomide Phase 2 trial dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $11.0M, net loss $20.5M ($0.18/sh); full-year net loss $105.0M ($1.27/sh).","Cash, equivalents and marketable securities $297.1M as of Dec 31, 2025; runway to end of 2028.","First patient dosed in Phase 2 MOMENTUM trial of cemsidomide for multiple myeloma; designed for accelerated approval.","Phase 1b trial of cemsidomide + elranatamab (Pfizer supply) to initiate Q2 2026; collaboration agreement signed Oct 2025.","October 2025 raised $125M gross proceeds from underwritten offering; warrants could add $225M."],"consensus_eps_estimate":-0.3098,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":35947000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106940,"accession_number":"0001628280-26-002010","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"C4 Therapeutics outlines milestones through 2028; cemsidomide Phase 2 trial on track for Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cemsidomide Phase 2 MOMENTUM trial to begin Q1 2026; recommended Phase 2 dose 100 µg.","Phase 1b combination with elranatamab to start Q2 2026; potential accelerated approval path for 4L+ by end 2028.","Phase 1 data: 40% ORR at 75 µg, 53% ORR at 100 µg in heavily pretreated multiple myeloma patients.","Cash runway to end 2028 provides funding through key value inflection points including NDA submission.","Internal discovery strategy targeting inflammation and neurodegeneration; up to 3 IND applications by end 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123271,"accession_number":"0001628280-25-049850","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics reports Q3 net loss $32.2M, raises $125M; cemsidomide 53% ORR at 100 µg","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.2M, net loss $32.2M ($0.44 EPS) vs $15.4M revenue and $24.7M loss in Q3 2024.","Completed equity offering of $125M gross proceeds in Oct 2025; potential additional $225M from warrants.","Phase 1 cemsidomide data: 53% ORR at 100 µg dose; one patient achieved MRD-negative complete response.","Entered clinical trial collaboration with Pfizer to evaluate cemsidomide + elranatamab; Pfizer supplies drug at no cost.","Cash $199.8M as of Sep 30, excluding $125M raise; runway extended to end of 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":24931000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123270,"accession_number":"0001628280-25-045157","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"C4 Therapeutics posts Phase 1 cemsidomide data in RRMM; terminates TD Cowen ATM prospectus","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Posted Phase 1 data for cemsidomide + dex in relapsed/refractory multiple myeloma; presentation on IR website.","Terminated sales agreement prospectus with TD Cowen effective Oct 16, 2025; underlying agreement remains in effect.","Previously issued 3,769,483 shares under TD Cowen ATM for gross proceeds of $9.6M as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123269,"accession_number":"0001193125-25-241591","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"C4 Therapeutics raises $117M net in underwritten offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 21.9M shares, pre-funded warrants for 28.7M shares, and Class A/B warrants for 50.6M shares each.","Combined price per unit $2.47; net proceeds ~$117M, extending cash runway to end of 2028.","If all warrants cash exercised, total net proceeds could reach $341.7M.","Class A warrants expire on earlier of 30 days post Phase 1b data or 5 years; Class B warrants mandatory if stock >$6.66.","Pre-funded warrants have $0.0001 exercise price and no expiration; all warrants subject to beneficial ownership limits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123268,"accession_number":"0001628280-25-043290","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"C4 Therapeutics Enters Clinical Trial Collaboration with Pfizer for Multiple Myeloma Drug Combination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["C4 Therapeutics and Pfizer signed a clinical trial collaboration and supply agreement for elranatamab and cemsidomide.","Pfizer will supply elranatamab (ELREXFIO) at no cost for a Phase 1b trial in relapsed/refractory multiple myeloma.","The Phase 1b trial will evaluate cemsidomide, dexamethasone, and elranatamab as second-line or later therapy.","Trial expected to start in Q2 2026; C4 Therapeutics sponsors and conducts the trial.","C4 Therapeutics CEO noted potential to improve outcomes and combine with a growing standard-of-care bispecific."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139941,"accession_number":"0001628280-25-042245","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"C4 Therapeutics Phase 1 cemsidomide shows 50% ORR at 100 µg in RRMM; Phase 2 planned Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50% ORR at 100 µg and 40% ORR at 75 µg cemsidomide + dex in heavily pre-treated RRMM; median DOR 9.3 mo overall.","No cemsidomide-related discontinuations; minimal dose reductions (6%); low rates of febrile neutropenia (4% Grade 3, 1% Grade 4).","Phase 2 single-arm registrational trial in 4th line+ starts Q1 2026; Phase 1b with BCMA BiTE in 2nd line+ starts Q2 2026.","72 patients enrolled; median 7 prior therapies; 75% had prior CAR-T or T-cell engager therapy; data cutoff July 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139940,"accession_number":"0001628280-25-038576","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"C4 Therapeutics Q2 net loss $26M; cemsidomide MM ORR 40-50%; FDA align on Phase 2 dose by YE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.0M ($0.37/share) on revenue $6.5M, down from $12.0M YoY.","Cemsidomide Phase 1 MM data: ORR 40% at 75 µg and 50% at 100 µg; well-tolerated; highest dose 100 µg.","Productive Type C meeting with FDA; registrational development expected to start early 2026; full data at IMS September 2025.","Cash $223M as of June 30, 2025; runway extended to mid-2027.","Preclinical milestone achieved under Merck KGaA collaboration; $1M earned."],"consensus_eps_estimate":-0.3917,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":13701000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157552,"accession_number":"0001628280-25-032155","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"C4 Therapeutics shareholders approve doubling authorized common shares to 300M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Ronald Cooper, Donna Grogan, and Steven Hoerter as Class II directors for terms expiring 2028.","Non-binding advisory vote on executive compensation passed with 48.85M for vs 0.89M against.","Ratification of KPMG as auditor for FY2025 approved with 60.18M for, 0.08M against.","Amendment to increase authorized common shares from 150M to 300M approved with 39.55M for, 20.66M against.","Certificate of Amendment filed and effective June 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157551,"accession_number":"0001628280-25-022864","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"C4 Therapeutics Q1 net loss $26.3M; cemsidomide 50% ORR at 100 µg in MM","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.2M (up from $3.0M YoY); net loss $0.37/share vs $0.41.","Cemsidomide Phase 1 MM dose escalation complete; 100 µg QD safe for expansion; ORR 50% at 100 µg, 40% at 75 µg.","One patient achieved MRD-negative complete response after prior T-cell engager therapies.","Will not advance CFT1946 beyond Phase 1; seeking partnership for BRAF program.","Cash $234.7M, runway into 2027; earned $4M from two Roche preclinical milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":7238000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157550,"accession_number":"0001628280-25-017612","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Bruce Downey to retire from Board, will not seek reelection at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Downey notified board of retirement effective after 2025 Annual Meeting of Stockholders.","Decision not due to any disagreement with company's strategy, operations, policies, or practices.","Will cease as chair and member of Organization, Leadership and Compensation Committee, Audit Committee, and Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175921,"accession_number":"0001628280-25-008429","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics reports FY2024 revenue $35.6M, net loss $1.52/sh; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $35.6M (vs $20.8M in FY2023); net loss $105.3M ($1.52/sh) vs $132.5M ($2.67).","Cash $267.3M at Dec 31, 2024; expected to fund operations into 2027.","Cemsidomide dose escalation continues; next-phase trials expected to start in early 2026.","CFT1946 Phase 1/2 progressing; data in melanoma and CRC expected H2 2025.","Appointed Steve Hoerter to board; initiated CFT8919 Phase 1 in Greater China with Betta."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":35584000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175920,"accession_number":"0001628280-25-001433","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics unveils 2025 milestones; cash runway extended into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities as of Dec 31, 2024 expected to fund operations into 2027.","Cemsidomide Phase 1 dose escalation in multiple myeloma and NHL to complete in 2H 2025; next-phase studies to start early 2026.","CFT1946 monotherapy dose escalation in BRAF V600 solid tumors to complete 1H 2025; Phase 1 data in melanoma and CRC expected 2H 2025.","CFT8919 Phase 1 data from partner Betta in China will inform future development outside China."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192837,"accession_number":"0001628280-24-050349","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"C4 Therapeutics presents cemsidomide Phase 1 data: 36% ORR in MM, 44% ORR in PTCL at ASH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In MM with dexamethasone, 36% ORR and 45% CBR at 75 µg QD; no dose reductions due to AEs.","In NHL monotherapy, 38% ORR across subtypes; in PTCL, 44% ORR and 19% complete metabolic response rate.","Neutropenia manageable; no discontinuations due to neutropenia; MTD not yet reached.","Next steps: complete Phase 1 dose escalation, initiate combo trials, engage regulators on path.","Data support potential best-in-class IKZF1/3 degrader for MM and NHL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192836,"accession_number":"0001628280-24-048593","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics appoints Steve Hoerter, former Deciphera CEO, to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven L. Hoerter appointed as Class II director effective November 19, 2024; serves until 2025 annual meeting.","Hoerter has over 30 years of oncology leadership; was CEO of Deciphera (acquired by ONO for $2.4B).","Granted 65,000 stock options under 2020 Plan; vests 1/3 on first anniversary, remainder quarterly over 2 years.","Board determined Hoerter independent per Nasdaq standards; brings commercialization expertise to guide pipeline.","Hoerter also serves on ORIC Pharmaceuticals board; previously led QINLOCK and TIBSOVO launches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192835,"accession_number":"0001628280-24-044409","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics reports Q3 2024 revenue $15.4M; net loss narrows to $0.35/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue rose to $15.4M (up 39% YoY) driven by an $8M Biogen milestone and $2.9M from Betta license.","Net loss improved to $24.7M from $27.0M YoY; diluted EPS of -$0.35 vs -$0.55.","Cash, equivalents and marketable securities $284.4M at Sep 30; expected runway into 2027.","Cemsidomide Phase 1/2 trial enrolling; MM and NHL data to be presented at ASH Dec 2024.","Appointed Paige Mahaney as Chief Scientific Officer; delivered second Biogen development candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":30407000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192832,"accession_number":"0001628280-24-042879","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K/A","filed_at":"2024-10-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics appoints Paige Mahaney as CSO effective Oct 28; Stewart Fisher retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paige Mahaney, Ph.D., formerly SVP at Exelixis, appointed CSO effective October 28, 2024.","Stewart Fisher, Ph.D., retires as CSO Oct 28, will serve as Senior Scientific Advisor through Dec 2024, then consultant through Dec 2025.","Mahaney receives $510k base salary, $150k sign-on bonus, up to $75k relocation, and performance bonus up to 40% of base.","Mahaney granted inducement option for 345,600 shares (25% vests at 1 yr, rest over 3 yrs) and RSUs for 76,800 shares (vest over 4 yrs).","Fisher's retirement not due to any disagreement; consulting agreement provides continued equity vesting through Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192834,"accession_number":"0001628280-24-042833","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics appoints Paige Mahaney as CSO; Stewart Fisher retires effective Oct 28","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paige Mahaney, Ph.D., appointed Chief Scientific Officer effective October 28, 2024; succeeds Stewart Fisher.","Fisher will remain as Senior Scientific Advisor through Dec 31, 2024, then consultant through Dec 31, 2025.","Mahaney joins from Exelixis; receives $510K base salary, $150K sign-on bonus, and 345,600 stock options.","Fisher's retirement not due to any disagreement; entered consulting agreement for continued vesting of equity.","Mahaney brings over 25 years pharma experience, most recently SVP of drug discovery at Exelixis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192833,"accession_number":"0001628280-24-042728","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"C4 Therapeutics board requires shareholder approval for stock option repricing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Amendment No. 1 to the 2020 Stock Option and Incentive Plan on Oct 7, 2024.","Amendment requires stockholder approval for any reduction in exercise price or repricing of stock options or SARs.","Previous administrator authority to reprice without stockholder approval is removed.","Amendment is effective immediately and does not require stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209252,"accession_number":"0001628280-24-039023","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics appoints Steve Fawell to board; Malcolm Salter retires after nearly a decade","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Malcolm Salter resigned from board effective August 29, 2024, after ~9 years; no disagreements.","Stephen Fawell, Ph.D. appointed as Class III director through 2026 annual meeting; granted 65,000 share options.","Fawell has 35 years drug discovery experience, most recently VP head of oncology small molecule discovery at AstraZeneca.","Ronald Cooper appointed chair of Nominating and Corporate Governance Committee; Bruce Downey added to Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209251,"accession_number":"0001628280-24-033874","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics Q2 net loss narrows to $17.7M; cash $295.7M; CFT1946 ESMO data Sept 14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.0M vs $2.7M YoY, driven by $8M Biogen milestone.","Net loss $17.7M ($0.26 per share) vs $35.9M ($0.73) in Q2 2023.","Cash $295.7M; expects runway into 2027.","CFT1946 Phase 1 monotherapy data to be presented at ESMO Congress 2024 on Sept 14.","Cemsidomide Phase 1 data in MM and NHL on track for Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":15045000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227195,"accession_number":"0001628280-24-029301","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"C4 Therapeutics stockholders elect three Class I directors, approve say-on-pay, ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Kenneth Anderson re-elected with 38.0M for, 8.6M withheld; Laura Bessen with 37.7M for, 8.8M withheld; Owen Hughes with 27.5M for, 19.1M withheld.","Advisory say-on-pay passed: 34.5M for, 11.9M against, 0.1M abstain.","KPMG LLP ratified as independent auditor for FY2024: 54.4M for, 0.2M against, 0 abstain.","No other matters were voted on at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227194,"accession_number":"0001628280-24-027399","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics appoints Ron Cooper as Chairman; Glenn Dubin resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ron Cooper appointed Chairman and director effective June 7, 2024, replacing Bruce Downey who remains a board member.","Director Glenn Dubin resigned effective same date; no disagreements with company.","Cooper granted stock options for 65,000 shares under 2020 Plan; one-third vests after one year, rest quarterly over two years.","Cooper brings experience as former CEO of Albireo (acquired by Ipsen) and nearly 30 years at Bristol-Myers Squibb."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227193,"accession_number":"0001628280-24-021367","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics Q1 net loss narrows to $28.4M; cash $299M into 2027; Biogen milestone $8M, Merck deal up to $740M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.0M (down from $3.8M YoY); net loss per share $0.41 vs $0.71.","Cash $299.2M as of Mar 31; expected runway into 2027.","Earned $8M from Biogen; Merck KGaA collaboration with $16M upfront and up to $740M milestones.","Phase 1 trials for cemsidomide (MM/NHL) and CFT1946 (solid tumors) progressing; data expected 2H 2024.","Appointed Dan Powers as SVP clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":3039000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246085,"accession_number":"0001628280-24-009967","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"C4 Therapeutics reprices underwater employee options; new exercise prices $19.00 and $11.88","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eligible options with exercise price >$22.00 repriced to $19.00 for senior leadership and $11.88 for other employees.","Repricing applies to CFO, CBO, CSO, CPO, and CLO; CEO and non-employee directors excluded.","Repriced options revert to original exercise price if holder is terminated for cause or resigns before March 7, 2025.","Board and Committee designed repricing as retention incentive without additional equity grants or cash compensation.","Original exercise price threshold of $22.00 is over 2x the closing price and about 2.5x the 30-day VWAP on effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246084,"accession_number":"0001628280-24-008339","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics enters collaboration with Merck KGaA for two protein degraders; $16M upfront, up to $740M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $16 million from Merck KGaA; Merck to fund discovery research costs.","C4T eligible for up to approximately $740 million in discovery, regulatory, and commercial milestone payments.","Tiered royalties on net sales: mid-single to low-double digit percent.","Collaboration on two targeted protein degraders from C4T's internal oncology pipeline.","Merck KGaA responsible for clinical development and commercialization; C4T uses TORPEDO platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246083,"accession_number":"0001628280-24-006142","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics reports FY2023 net loss of $132.5M; cash runway extended into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 was $132.5M ($2.67 per share) vs $128.2M ($2.62) in FY2022.","Revenue fell to $20.8M from $31.1M, mainly due to end of Calico collaboration.","Cash, equivalents and marketable securities at Dec 31, 2023: $281.7M; proforma ~$330M with Jan 2024 inflows, funding into 2027.","Workforce reduced ~30% in Jan 2024; trials for CFT7455 and CFT1946 continue, data expected 2H2024.","Collaborations: Merck deal up to $2.5B milestone potential; Betta paid $25M, CTA approved in China."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":20756000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246082,"accession_number":"0001628280-24-001085","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"C4 Therapeutics posts investor presentation; announces restructuring to preserve cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company posted investor presentation on January 11, 2024, detailing a restructuring plan.","Restructuring expected to preserve cash runway into 2027.","Estimated charges and costs for restructuring to be incurred in connection with cost-saving initiatives.","Forward-looking statements include expectations on timing, costs, and efficiencies from the restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246081,"accession_number":"0001628280-24-000947","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics cuts workforce 30%, narrows focus on two clinical programs, reports $330M cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~30% (45 positions) substantially complete by end of Q1 2024; estimated charges of ~$3M.","Unaudited cash, equivalents, and marketable securities of ~$330M as of Jan 5, 2024; expects cash runway into 2027.","Raised ~$107M: $25M Betta equity, $10M Merck upfront, $72M net from ATM (13.7M shares at avg $5.42).","Prioritizes CFT7455 (multiple myeloma/NHL) and CFT1946 (solid tumors) Phase 1/2 trials; data in 2H 2024.","Supports CFT8919 partner trial (Betta) and collaborations with Roche, Biogen, Merck; internal discovery streamlined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263547,"accession_number":"0001628280-23-041317","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"C4 Therapeutics announces positive Phase 1 data for CFT7455 in relapsed/refractory multiple myeloma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Monotherapy dose escalation complete; 22 patients, median 7 prior therapies; 1 PR at 75 µg daily in BCMA-refractory patient.","Combination with dexamethasone: 9 patients; 1 sCR and 1 PR at 37.5 µg daily, both BCMA refractory.","CFT7455 well tolerated; no DLTs leading to discontinuation; common Grade 3+ AE: neutropenia (n=11).","Optimal dosing schedule 14 days on/14 days off; immunomodulatory CD8+ T-cell activation observed.","Dose escalation continues for combination and NHL; full Phase 1 data expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263546,"accession_number":"0001628280-23-041271","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics enters license and collaboration agreement with Merck to develop degrader-antibody conjugates","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["C4T grants Merck worldwide exclusive license for DACs directed to an initial undisclosed oncology target.","Merck pays $10 million upfront; C4T eligible for up to ~$600 million in milestones for initial target plus tiered royalties.","Merck has options for three additional targets; if all exercised, total potential payments to C4T up to ~$2.5 billion.","Collaboration leverages C4T's TORPEDO platform for degrader payloads and Merck's antibody conjugation expertise.","Merck responsible for all development, regulatory, manufacturing, and commercialization costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263545,"accession_number":"0001628280-23-039562","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"C4 Therapeutics appoints Owen Hughes to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Owen Hughes appointed as Class I director, term until 2024 annual meeting.","Hughes co-founded Cullinan Oncology, raised over $400M in IPO, served as CEO.","Received options for 52,000 shares vesting over three years under 2020 plan.","Indemnification agreement entered in same form as other directors.","Hughes also chairs XOMA, Ikena Oncology; previously on boards of Radius, Translate Bio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263544,"accession_number":"0001628280-23-035790","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics discontinues CFT8634 BRD9 degrader; Q3 net loss $27.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFT8634 Phase 1 dose escalation failed to show sufficient single-agent efficacy in synovial sarcoma and SMARCB1-null tumors despite high BRD9 degradation; wind-down by Q1 2024.","Net loss $27.0M ($0.55 per share) vs $32.0M ($0.65) in Q3 2022; revenue $11.1M (up from $6.8M) from Roche and Biogen collaborations.","Cash, equivalents and marketable securities $246.4M as of Sept 30, 2023; expected runway into H2 2025.","CFT7455 Phase 1 dose escalation completed in monotherapy for R/R MM; combination arm continues; virtual event on Dec 12, 2023.","Kendra Adams appointed CFO in September 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280754,"accession_number":"0001628280-23-031375","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"C4 Therapeutics CFO Lauren White to step down; Kendra Adams named successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lauren White resigns as CFO, Treasurer, and principal financial/accounting officer effective September 15, 2023; no disagreement cited.","Kendra Adams appointed CFO effective September 18, 2023; previously SVP, Communications and IR at C4T since Nov 2020.","Mark Mossler appointed Chief Accounting Officer and principal accounting officer effective Sept 18, 2023; previously VP, Corporate Controller since June 2023.","Adams receives $450K base salary, 40% bonus target, option for 111,000 shares, and 25,000 RSUs.","Mossler receives $315K base salary, 30% bonus target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280753,"accession_number":"0001628280-23-027935","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics Q2 net loss $35.9M; cash $286.7M; signs CFT8919 license deal with Betta","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.9M ($0.73 per share) vs $27.4M ($0.56) in Q2 2022; revenue fell to $2.7M from $13.8M.","Cash, equivalents and marketable securities $286.7M as of June 30, expected to fund ops into 2H 2025.","Exclusive license for CFT8919 (EGFR L858R degrader) with Betta Pharma in Greater China: $10M upfront, $25M equity investment, up to $357M milestones plus royalties.","U.S. IND cleared for CFT8919; Phase 1/2 trials for CFT7455, CFT8634, CFT1946 ongoing; Phase 1 dose escalation data expected 2H 2023.","Appointed Len Reyno as CMO and Mary Christian as SVP Regulatory in July 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":6423000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299383,"accession_number":"0001628280-23-022597","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"C4 Therapeutics appoints Leonard Reyno, M.D. as Chief Medical Officer effective July 10, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Reyno receives $550K base salary, $200K sign-on bonus, and up to 40% performance bonus.","Inducement option for 276,000 shares (25% vests year 1, rest quarterly over three years) plus 61,300 RSUs vesting over four years.","Reyno brings ~30 years of oncology clinical experience; previously led Padcev early development, Herceptin and Taxotere FDA approvals.","Stockholders elected three Class III directors, approved executive compensation, ratified KPMG as auditor, and approved officer liability limitation charter amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299382,"accession_number":"0001628280-23-020025","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"C4 Therapeutics licenses CFT8919 to Betta Pharma for Greater China; receives $35M upfront/equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$10M upfront cash + $25M equity investment from Betta affiliate at $4.49/share (10.2% ownership).","Up to $357M in development/commercial milestones plus low-to-mid double-digit royalties on Greater China sales.","C4T retains rights outside Greater China; eligible for low single-digit royalties on ex-China sales.","CFT8919 is an oral BiDAC degrader targeting EGFR L858R NSCLC; IND submission to FDA expected H1 2023.","Betta responsible for development/manufacturing/commercialization in licensed territories; C4T retains rest of world."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299381,"accession_number":"0001628280-23-015454","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics Q1 net loss widens to $34.8M; cash runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.8M ($0.71 per share) vs. $31.6M ($0.65) in Q1 2022; revenue dropped to $3.8M from $7.7M.","R&D expense rose to $29.0M (Q1 2022: $26.2M) driven by clinical trial costs for CFT7455, CFT8634, CFT1946.","Cash, equivalents and marketable securities were $305.0M as of March 31, 2023, expected to fund operations into 2025.","Phase 1 dose-escalation data for CFT7455 (monotherapy in multiple myeloma) and CFT8634 (synovial sarcoma) expected in H2 2023.","IND submission for CFT8919 (NSCLC) targeted for H1 2023; first patient dosed in CFT1946 Phase 1/2 trial in January."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":3759000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319539,"accession_number":"0001662579-23-000040","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics Reports Q4 and Full Year 2022 Financial Results with Net Loss of $128.2M and Cash Runway to End of 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for 2022 was $31.1M, down from $45.8M in 2021, primarily due to one-time recognition in prior year from Roche agreement termination.","Net loss for 2022 was $128.2M ($2.62 per share) compared to $83.9M ($1.82 per share) in 2021, driven by increased R&D and G&A expenses.","Cash, cash equivalents and marketable securities totaled $337.1M as of Dec 31, 2022, expected to fund operations through end of 2024.","Phase 1 dose escalation data for CFT7455 (multiple myeloma) and CFT8634 (synovial sarcoma) expected in second half of 2023.","IND submission for CFT8919 (EGFR L858R degrader) on track for first half of 2023; CFT1946 Phase 1/2 trial dosing first patient in January 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":31096000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319536,"accession_number":"0001628280-23-004835","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K/A","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics FY2022 net loss $128.2M; cash runway to end 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $31.1M in FY2022, down from $45.8M in FY2021 due to Roche agreement termination.","Net loss $128.2M ($2.62/share) vs. $83.9M ($1.82/share) in FY2021; R&D spend rose to $117.8M.","Cash, equivalents and marketable securities $337.1M at Dec 31, 2022, down from $451.5M.","Phase 1 dose escalation data for CFT7455 (MM) and CFT8634 (synovial sarcoma) expected 2H 2023.","IND submission for CFT8919 (EGFR L858R) on track for 1H 2023; CFT1946 trial dosing patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":31096000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319538,"accession_number":"0001628280-23-002041","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"C4 Therapeutics CMO Adam Crystal resigns; Hagop Youssoufian named interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam S. Crystal, M.D., Ph.D., resigns as CMO effective Feb 24, 2023 to pursue a head of R&D opportunity elsewhere.","Crystal will provide transitional consulting services on an as-needed basis until Sep 1, 2023.","Hagop Youssoufian, M.D., appointed interim CMO effective Feb 24, 2023; permanent search underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319537,"accession_number":"0001628280-23-000725","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"C4 Therapeutics announces 2023 priorities, Phase 1 data expected in 2H 2023 for CFT7455 and CFT8634","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $366M as of Sep 30, 2022; expected to fund operations to end of 2024.","Phase 1/2 trial of CFT7455 (IKZF1/3 degrader for multiple myeloma) continues; Phase 1 dose escalation data expected in 2H 2023.","Phase 1/2 trial of CFT8634 (BRD9 degrader for synovial sarcoma) continues; Phase 1 data expected in 2H 2023; PK/PD data supportive of proof of mechanism.","Phase 1/2 trial of CFT1946 (BRAF-V600 degrader for solid tumors) initiated; IND submission for CFT8919 (EGFR L858R NSCLC) planned in 1H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337719,"accession_number":"0001628280-22-027966","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"C4 Therapeutics Q3 net loss widens to $32.0M; cash runway to end of 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.0M ($0.65/diluted share) vs $24.7M ($0.51) in Q3 2021; revenue $6.8M vs $8.5M.","Cash, equivalents & marketable securities $366.0M at Sep 30, down from $451.5M at Dec 31, 2021; runway to end of 2024.","Phase 1/2 trials for CFT7455 (IKZF1/3 degrader in MM/NHL) and CFT8634 (BRD9 in synovial sarcoma) advancing dose escalation.","IND clearance for CFT1946 (BRAF-V600 degrader) in Sep; Phase 1/2 to initiate by year-end 2022.","Upcoming milestones: CFT8919 (EGFR L858R) IND-enabling activities to complete by year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":28242000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355102,"accession_number":"0001628280-22-025322","cik":1662579,"company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","form_type":"8-K/A","filed_at":"2022-09-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"C4 Therapeutics board adopts annual advisory vote on exec compensation after stockholder recommendation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted in favor of a 1-year frequency for advisory votes on named executive officer compensation.","Board determined to hold annual non-binding advisory votes until the next required frequency proposal.","Amendment filed solely to disclose this frequency decision; original 8-K reported June 22, 2022 annual meeting results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":413510328.2784759,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-22T23:59:59+00:00|355102"}